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Respiratory infections can cause wheezing episodes in chil-
dren and can influence the onset and severity of asthma via 
complex and intersecting mechanisms. Infections can trigger 
atopic asthma, and atopy can cause wheezing during airway in-
fections and modify the course of airway infections. Mycoplas-
ma pneumoniae (M. pneumoniae), primarily recognized as a 
causative agent of community-acquired pneumonia, has re-
cently been linked to asthma. Infections with M. pneumoniae 
can precede the onset of asthma, exacerbate asthmatic symp-
toms, and cause difficulties with asthma management.
1
The clinical association between M. pneumoniae infection 
and exacerbation of asthma symptoms has been suspected for 
longer than two decades; however, the nature of the correlation 
is still far from clear. In 1970, Berkovich et al.
2 provided the first 
prospective study showing serological evidence of infection 
with either M. pneumoniae or a respiratory virus in 27 of 84 
(32%) asthma patients. Huhti et al.
3 analyzed 63 patients after 
severe episodes of acute asthma and found that 19% had asso-
ciated viral or mycoplasma infections. Biscardi et al.
4 reported 
that 20% (24/119) of the patients with previously diagnosed 
asthma had simultaneous acute M. pneumoniae infection and 
asthma exacerbation; of 51 patients experiencing their first epi-
sode, acute infection with M. pneumoniae was identified in 26 
(50%) of the patients. Therefore, based on the current literature, 
M. pneumoniae appears to be an important trigger for the acute 
exacerbation of asthma, accounting for 3.3%-50% of exacerba-
tions.
Several recent studies have implicated M. pneumoniae infec-
tion in the pathophysiology of asthma in subsets of patients. In 
two of the most influential studies, Kraft et al.
5 and Martin et al.
6 
used polymerase chain reactions (PCRs) to detect M. pneu-
moniae in the lower pulmonary airways in 25 of 55 (45%) adult 
patients with chronic stable asthma, compared with 1 of 11 
(9%) controls. Using serology and PCR, Esposito et al.
7 found M. 
pneumoniae significantly more often in children with acute ep-
isodes of wheezing than in controls, and infection was signifi-
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cantly associated with a history of recurrent wheezing. Lieber-
man et al.
8 showed in a prospective study using serological de-
tection that M. pneumoniae infection was significantly associ-
ated with acute exacerbation of bronchial asthma. Further-
more, treatment with antibiotics against M. pneumoniae signif-
icantly improved pulmonary function in asthmatics with M. 
pneumoniae infection, suggesting a role for infection in chronic 
asthmatics.
9
Although the evidence linking M. pneumoniae infection with 
exacerbation and chronic asthma is convincing, the role of M. 
pneumoniae as the cause of the initial onset of asthma remains 
unclear. In 1994, Yano et al.
10 was first to describe a patient in 
whom a previous acute mycoplasmal respiratory infection led 
to an initial onset of bronchial asthma. In a follow-up study in 
50 children, Mok et al.
11 reported that five children (10%) with 
M. pneumoniae respiratory illness developed clinical signs of 
asthma. All five children, however, had a family and personal 
history of atopy. It seems that acute infection with M. pneu-
moniae can initiate asthma in some previously asymptomatic 
patients and in some individuals with atopy. However, regard-
ing a quantitative role of these bacteria or a direct cause-and-
effect association as asthma initiators, additional large popula-
tion-based prospective or cohort studies are necessary before 
definitive conclusions can be drawn.
The mechanisms of M. pneumoniae interactions with human 
airways are complex and multifactorial. Underlying mecha-
nisms of M. pneumoniae infection-induced or exacerbated 
asthma may involve the stimulation of predisposing immune 
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responses. Factors involved in these immune responses may 
include the induction of Th2 cytokines, immune cells, and IgE 
production; physiological changes such as bronchial obstruc-
tion, angiogenesis, edema, and cell wall thickening; and even 
neural mechanisms.
5,6,10-12 Further elucidation of these mecha-
nisms may enable the development of novel therapeutic strate-
gies for the prevention and treatment of infection-induced 
asthma. The immune cells of bronchoalveolar lavage fluid in 
children with M. pneumoniae pneumonia were found to com-
prise high percentages of neutrophils and lymphocytes.
12 Thus, 
the exacerbation of asthma may be related to neutrophil cyto-
kine signaling and degranulation, and cell lysis at the respirato-
ry epithelial cell surface.
13,14 In addition, asthmatics with infec-
tion had a significantly greater number of mast cells than asth-
ma patients without infection.
6 These observations suggest that 
M. pneumoniae infections, particularly in children, may result 
in a dominant Th2 response that induces increased IgE release, 
thereby predisposing patients to atopy.
Increased airway wall thickness has been observed in several 
different studies in asthma patients. Continued function re-
quires extensive microvascular systems, and adding thickness 
to the airway wall further reduces airway conductance.
15 Angio-
genesis and edema have been associated with airway remodel-
ing in asthma. These responses to M. pneumoniae infection of 
the airways may induce chronic asthma.
16 However, studies 
about how this feature of asthma is affected during bacterial in-
fection and the impact on treatment of the disease have only 
recently commenced.
Animal models of chronic airway infection with M. pulmonis 
(the murine equivalent of human M. pneumoniae) have been 
used to describe the mechanisms underlying angiogenesis, 
vascular remodeling, and airway wall thickening observed in 
asthma.
15 Airway remodeling results from inflammatory re-
sponses that allow the movement of leukocytes and plasma 
proteins into the airway epithelium. This vascular leakage is 
promoted by vascular endothelial growth factor (VEGF).
15
As presented in this issue of Allergy, Asthma & Immunology 
Research, Jeong et al.
17 investigated the changes in VEGF and 
interleukin-5 (IL-5) serum levels in atopic children with M. 
pneumoniae pneumonia. The authors showed that the serum 
levels of VEGF and IL-5 were increased in atopic children with 
mycoplasma pneumonia compared with levels in other groups. 
Furthermore, the serum levels of VEGF and IL-5 were increased 
at the recovery phase compared with the admission phase. 
These results suggest an association between M. pneumoniae 
infection and VEGF or IL-5 in the pathogenesis of atopic asth-
ma in children. A limitation to this study was the reliance on the 
past and family history of allergic diseases and IgE concentra-
tion to define atopy. Future studies will require a more defini-
tive definition of atopy in study subjects. In addition, a long-
term follow-up study examining the development of asthma in 
non-atopic individuals with mycoplasma infection would be 
interesting. Further research will be required to demonstrate a 
link between the development of hypersensitivity and M. pneu-
moniae infection.
Despite recent advances in diagnostic technology and the de-
velopment of animal models representative of human disease, 
well-designed and controlled human clinical studies and ex-
perimentation with animal models are needed to elucidate the 
role of M. pneumoniae infection in the predisposition for or 
protection from asthma. Future large, general population-
based prospective studies will be necessary to investigate the 
development of asthma induced by M. pneumoniae infection 
in humans.
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